The new 1,500m2 facility will expand the company’s large-scale viral vectors production capabilities for vaccines and gene therapy. It has been designed to meet the increasing demand for
Brukinsa has been approved to treat relapsed/refractory (R/R) MZL adult patients who have previously received at least one anti-CD20-based therapy. The Bruton’s tyrosine kinase (BTK) small molecule inhibitor,
Under the deal terms, the company obtained an exclusive option for evaluating the regulatory, clinical development and commercialisation plan for CWRU’s intellectual property portfolio for up to 12
Under the collaboration, the company will be responsible for the vaccine epitope selection portion using its in silico vaccine design toolkit, iVAX. EpiVax will work as a subgrantee
Characterised by recurrent inflammation of the skin associated with intense pruritus, AD is a non-contagious chronic, inflammatory disease of the skin. Almirall has submitted the application based on
Under the collaboration, AmbioPharm will help Ariceum in manufacturing and supplying cGMP peptide conjugates. The peptide conjugates will be radio-labelled as the radiopharmaceutical end-product and will be used
The financial details of the agreement are not disclosed by the companies. Under the deal, CSL will acquire exclusive and global license to TS23, an enhanced first-in-class anti-α2-antiplasmin
Led by Canaan Ventures, the financing round has seen participation from Taiho Ventures, Osage University Partners, and Sanofi Ventures. Normunity intends to use the funds for advancing its
The regulator has accepted the company’ new drug application (NDA) for the combination therapy and as continuation of quizartinib monotherapy after consolidation to treat FLT3-ITD–positive AML patients. Quizartinib,
If approved by the regulatory agency, neffy would be the first non-injectable treatment available to patients suffering with allergic reactions of Type I, including anaphylaxis. The regulatory body has
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.